클로자핀 중단 이후 처방 패턴의 변화: 후향적 의무기록 분석
Change of Prescribing Pattern after Clozapine Discontinuation: A Retrospective Chart Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Despite the high discontinuation rate of clozapine in refractory schizophrenia, there is limited evidence regarding the suggested treatment after clozapine discontinuation. Methods: The medical records of 37 patients who discontinued clozapine were retrospectively reviewed. The prescription patterns of antipsychotics, mood stabilizers, and antidepressants were compared at three points before and after clozapine treatment and at the most recent visit. Results: After clozapine discontinuation, 75.6% of the subjects were receiving antipsychotic polypharmacy, and 32.4% were taking more than 3 antipsychotics. The frequently used antipsychotics were olanzapine (21.5%), quetiapine (21.5%), and paliperidone (12.7%). The rates of augmentation with mood stabilizers and antidepressants were 43.2% and 29.7%, respectively. Furthermore, valproate was the most commonly used mood stabilizer (87.5%). Conclusion: Antipsychotic polypharmacy and augmentation are inevitable in schizophrenia patients for whom clozapine has been discontinued. Further research is required to improve the outcomes of polypharmacy and augmentation in schizophrenia patients.
Abstract
Objectives: Despite the high discontinuation rate of clozapine in refractory schizophrenia, there is limited evidence regarding the suggested treatment after clozapine discontinuation. Methods: The medical records of 37 patients who discontinued clozapine were retrospectively reviewed. The prescription patterns of antipsychotics, mood stabilizers, and antidepressants were compared at three points before and after clozapine treatment and at the most recent visit. Results: After clozapine discontinuation, 75.6% of the subjects were receiving antipsychotic polypharmacy, and 32.4% were taking more than 3 antipsychotics. The frequently used antipsychotics were olanzapine (21.5%), quetiapine (21.5%), and paliperidone (12.7%). The rates of augmentation with mood stabilizers and antidepressants were 43.2% and 29.7%, respectively. Furthermore, valproate was the most commonly used mood stabilizer (87.5%). Conclusion: Antipsychotic polypharmacy and augmentation are inevitable in schizophrenia patients for whom clozapine has been discontinued. Further research is required to improve the outcomes of polypharmacy and augmentation in schizophrenia patients.
참고문헌 (28)
- Psychosis and Schizophrenia in Adults: Treatment and Management: Updat-ed Edition 2014, "National Collaborating Centre for Mental Health (UK)", National Institute for Health and Care Excellence (UK), ~ (2014)
- McIlwain ME, "Pharmaco-therapy for treatment-resistant schizophrenia", Neuropsychiatr Dis Treat, 7, pp.135~149 (2011)
- Lewis SW, "Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in re-sistant schizophrenia", Schizophr Bull, 32, pp.715~723 (2006)
- McEvoy JP, "Effectiveness of clozapine versus olanzap-ine, quetiapine, and risperidone in patients with chronic schizo-phrenia who did not respond to prior atypical antipsychotic treat-ment", Am J Psychiatry, 163, pp.600~610 (2006)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Wheeler A, "Outcomes for schizo-phrenia patients with clozapine treatment: how good does it get?", J Psychopharmacol, 23, pp.957~965 (2009)
- Duggan A, "Modelling the impact of clozapine on suicide in patients with treatment-resistant schizo-phrenia in the UK", Br J Psychiatry, 182, pp.505~508 (2003)
- Brunette MF, "Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders", Schizophr Bull, 32, pp.637~643 (2006)
- Porcelli S, "Clozapine resistance: augmenta-tion strategies", Eur Neuropsychopharmacol, 22, pp.165~182 (2012)
- Siskind D, "Clozapine response rates among people with treatment-resistant schizophrenia: data from a system-atic review and meta-Analysis", Can J Psychiatry, 62, pp.772~777 (2017)
- Wagner E, "Clo-zapine augmetation strategies-a systematic meta-review of avail-able evidence. Treatment options for clozapine resistance", J Psycho-pharmacol, 33, pp.423~435 (2019)
- Muscatello MRA, "Augmentation strategies in partial responder and", or treatment-resistant schizophrenia patients treated with clozapine, 2014, pp.15, 2329~2345
- Berardis DD, "Safety of antipsychotics for the treatment of schizophre-nia : a focus on the adverse effects of clozapine", Ther Adv Drug Saf, 9, pp.237~256 (2018)
- Hayhurst KP, "The cost-effectiveness of clozap-ine: a controlled, population-based, mirror-image study", J Psycho-pharmacology, 16, pp.169~175 (2002)
- 강시현, "클로자핀 처방 패턴 및 클로자핀 중단과 관련된 임상 요인", 대한조현병학회지, 22(1), pp.2~7 (2019), 대한조현병학회[DOI]
- Gallego JA, "Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional tends from 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)
- 장진구, "일 대학병원 정신증 환자에서 항정신병약물 병용요법의 사용", 대한정신약물학회지, 24(2), pp.69~75 (2013), 대한정신약물학회
- 윤제연, "‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료", 대한조현병학회지, 22(2), pp.21~33 (2019), 대한조현병학회[DOI]
- Lee JS, "Kore-an Medication Algorithm for Schizophrenia 2019, Second Revi-sion: Treatment of Psychotic Symptoms", Clin Psychopharmacol Neu-roscience, 18, pp.386~394 (2020)
- Correll CU, "An-tipsychotic combinations vs monotherapy in schizophrenia: a me-ta-analysis of randomized controlled trials", Schizophr Bull, 35, pp.443~457 (2009)
- Galling B, "Antipsychotic augmentation vs monotherapy in schizophre-nia: systematic review, meta-analysis and meta-regression analy-sis", World Psychiatry, 16, pp.77~89 (2017)
- Guinart D, "Antipsychotic polypharmacy in schizophre-nia: why not?", J Clin Psychiatry, 83, pp.3~ (2020)
- Sinclair D, "Treatment resistant schizophrenia: a com-prehensive survey of randomised controlled trials", BMC Psychia-try, 12, pp.253~ (2014)
- Dold M, "Pharmacotherapy of treatment-resistant schizo-phrenia: a clinical perspective", Evid Based Ment Health, 17, pp.33~37 (2014)
- Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
- Luykx JJ, "In the af-termath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who dis-continue clozapine", Br J Psychiatry, 217, pp.498~505 (2020)
- Mao YM, "Augmentation with antidepressants in schizo-phrenia treatment: benefit or risk", Neuropsychiatr Dis Treat, 11, pp.701~713 (2015)
- Helfer B, "Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis", Am J Psy-chiatry, 173, pp.876~886 (2016)